Related references
Note: Only part of the references are listed.Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter?
Jack R. Andrews et al.
PROSTATE (2020)
Efficacy and Safety of Carboplatin Plus Paclitaxel as the First-, Second-, and Third-line Chemotherapy in Men With Castration-resistant Prostate Cancer
Maki Fujiwara et al.
CLINICAL GENITOURINARY CANCER (2019)
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
Ronald de Wit et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial
Paul G. Corn et al.
LANCET ONCOLOGY (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial
Esther W. Bouman-Wammes et al.
EUROPEAN JOURNAL OF CANCER (2018)
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
Rahul Aggarwal et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Cellular plasticity and the neuroendocrine phenotype in prostate cancer
Alastair H. Davies et al.
NATURE REVIEWS UROLOGY (2018)
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302
Johann S. de Bono et al.
EUROPEAN UROLOGY (2017)
Emerging Variants of Castration-Resistant Prostate Cancer
Panagiotis J. Vlachostergios et al.
CURRENT ONCOLOGY REPORTS (2017)
The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer
Mark M. Pomerantz et al.
CANCER (2017)
Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer
Heather H. Cheng et al.
EUROPEAN UROLOGY (2016)
Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): Results from the SU2C/PCF/AACRWest Coast Prostate Cancer Dream Team (WCDT).
Eric Jay Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies
Nader Al Nakouzi et al.
EUROPEAN UROLOGY (2015)
The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer
Michael T. Schweizer et al.
EUROPEAN UROLOGY (2014)
Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: US Food and Drug Administration Drug Approval Summary
Paul G. Kluetz et al.
CLINICAL CANCER RESEARCH (2013)
Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Previously Received Docetaxel: U.S. Food and Drug Administration Drug Approval Summary
Yangmin M. Ning et al.
CLINICAL CANCER RESEARCH (2013)
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer
R. J. van Soest et al.
EUROPEAN JOURNAL OF CANCER (2013)
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
C. Parker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer
Himisha Beltran et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer
Mari Nakabayashi et al.
BJU INTERNATIONAL (2008)
A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel
Robert W. Ross et al.
CANCER (2008)
Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer
A O'Donnell et al.
BRITISH JOURNAL OF CANCER (2004)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
